Autoimmune Gastritis
Conditions
Interventions
AIG Cluster 1(Part Two):none
AIG Cluster 2(Part Two):none
Control group(Part Two):none
AIG patient group (Part One):None
Sponsors
Army Medical Center of PLA
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Part 1 – Study Population (1) Age 18–75 years, both sexes eligible; (2) Confirmed autoimmune gastritis (AIG), defined by the fulfilment of at least one of the following two criteria: 1). Endoscopy: presence of marked corpus-predominant atrophy (i.e., lesser atrophy in the antrum than in the corpus/fundus) and/or histology showing atrophy of the corpus or fundus accompanied by neuroendocrine cell hyperplasia and loss of parietal cells; 2). Serology: positive anti-parietal cell antibodies and/or anti-intrinsic factor antibodies. 2.Part 2 – Inclusion Criteria (1)AIG Patients Age 18–75 years, either sex;(2) Confirmed autoimmune gastritis (AIG), defined by >=1 of the following: 1).Endoscopy: marked corpus-predominant atrophy (i.e., antral atrophy less pronounced than in the corpus/fundus) and/or histology showing corpus/fundus atrophy with neuroendocrine cell hyperplasia and loss of parietal cells;2).Serology: positive anti-parietal cell antibodies and/or anti-intrinsic factor antibodies; (3)No antibiotics, traditional Chinese medicines, or probiotics within the past month; (4)Voluntary participation, willingness to comply with the clinical trial protocol, and written informed consent. Control Subjects:(1) Age 18–75 years, either sex; (2)Endoscopic diagnosis of chronic non-atrophic gastritis and negative ¹4C or ¹³C urea breath test; (3)No antibiotics, traditional Chinese medicines, or probiotics within the past month;(4)Voluntary participation, willingness to comply with the clinical trial protocol, and written informed consent.
Exclusion criteria
Exclusion criteria: 1.Part 1 – Exclusion Criteria(1) Presence of any severe comorbidity that could interfere with study assessments (e.g., significant hepatic, renal, or cardiovascular disease); (2)Inability to provide informed consent or to understand and comply with routine diagnostic procedures and clinical evaluations. 2.Part 2 – Exclusion Criteria(1)Presence of any severe comorbidity that could interfere with study evaluations (e.g., significant hepatic, renal, or cardiovascular disease); (2)Pregnant or lactating women; (3)Inability to articulate symptoms or wishes accurately—such as in psychotic disorders or severe neuroses—or inability to understand and comply with routine diagnostic procedures and clinical assessments; (4)Any other condition considered by the investigator to render the patient unsuitable for enrollment (e.g., severe constipation or diarrhea).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The distribution of microbiota in saliva and feces; | — |
Countries
China
Contacts
Public ContactLan Chunhui
Army Medical Center of PLA
Outcome results
None listed